Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease
Retrieved on:
Tuesday, November 15, 2022
Kennedy Institute, Skin, Risk, Finger, Regulation of tobacco by the U.S. Food and Drug Administration, Injection, Inflammation, Drug development, Security (finance), Hardness, Ivey International Centre for Health Innovation, Medicines and Healthcare products Regulatory Agency, Recurrence, Adalimumab, Quality-adjusted life year, Patient, Rheumatoid arthritis, Health, Investigational New Drug, NHS, Medication, FDA, Growth, QALY, Capsular contracture, Food, University, Health care, Compte rendu, Partnership, Annual report, Life, Social work, Research, Safety, University of Oxford, IND, File, MHRA, Quality of life, Psoriasis, PALO, Pharmaceutical industry, Rheumatology
They extrapolated the trial results using a patient-level simulation model, which estimated the lifetime cost-effectiveness of adalimumab for treatment of Dupuytrens Disease.
Key Points:
- They extrapolated the trial results using a patient-level simulation model, which estimated the lifetime cost-effectiveness of adalimumab for treatment of Dupuytrens Disease.
- The researchers simulation found that repeated courses of intranodular injections of adalimumab are likely to be cost-effective for treating progressive early-stage Dupuytrens disease.
- Lead author, Dr Helen Dakin , University Research Lecturer at Oxford Population Healths Health Economics Research Centre, said: Adalimumab is likely to be a cost-effective treatment for progressive early-stage Dupuytrens disease.
- Our phase 2b data shows that Adalimumab has the potential to transform the management of progressive early-stage Dupuytrens disease.